MA23856A1 - Recombinant obese (ob) proteines - Google Patents

Recombinant obese (ob) proteines

Info

Publication number
MA23856A1
MA23856A1 MA24221A MA24221A MA23856A1 MA 23856 A1 MA23856 A1 MA 23856A1 MA 24221 A MA24221 A MA 24221A MA 24221 A MA24221 A MA 24221A MA 23856 A1 MA23856 A1 MA 23856A1
Authority
MA
Morocco
Prior art keywords
proteins
obese
recombinant
recombinant obese
Prior art date
Application number
MA24221A
Other languages
English (en)
Inventor
Rene Devos
Yves Guisez
Arthur Campfield
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA23856A1 publication Critical patent/MA23856A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
MA24221A 1995-05-05 1996-05-02 Recombinant obese (ob) proteines MA23856A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43577795A 1995-05-05 1995-05-05
US48462995A 1995-06-07 1995-06-07

Publications (1)

Publication Number Publication Date
MA23856A1 true MA23856A1 (fr) 1996-12-31

Family

ID=27030682

Family Applications (1)

Application Number Title Priority Date Filing Date
MA24221A MA23856A1 (fr) 1995-05-05 1996-05-02 Recombinant obese (ob) proteines

Country Status (35)

Country Link
US (1) US6025325A (fr)
EP (1) EP0741187A2 (fr)
JP (1) JP3244627B2 (fr)
KR (1) KR100219970B1 (fr)
CN (1) CN1157290A (fr)
AR (1) AR003087A1 (fr)
AU (1) AU688210B2 (fr)
BG (1) BG62975B1 (fr)
BR (1) BR9602166A (fr)
CA (1) CA2175298A1 (fr)
CZ (1) CZ129796A3 (fr)
DE (1) DE741187T1 (fr)
ES (1) ES2093593T1 (fr)
GR (1) GR960300075T1 (fr)
HR (1) HRP960213A2 (fr)
HU (1) HU220093B (fr)
IL (1) IL118059A0 (fr)
IS (1) IS4343A (fr)
MA (1) MA23856A1 (fr)
MY (1) MY132189A (fr)
NO (1) NO961796L (fr)
NZ (1) NZ286466A (fr)
OA (1) OA10362A (fr)
PE (1) PE50897A1 (fr)
PL (1) PL186568B1 (fr)
RO (1) RO117177B1 (fr)
RU (1) RU96109211A (fr)
SG (1) SG49337A1 (fr)
SK (1) SK56996A3 (fr)
SV (1) SV1996000030A (fr)
TN (1) TNSN96066A1 (fr)
TR (1) TR199600357A2 (fr)
TW (1) TW464655B (fr)
UY (1) UY24219A1 (fr)
YU (1) YU26596A (fr)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3504263B2 (ja) 1991-11-04 2004-03-08 ジェネティックス・インスチチュート・リミテッド・ライアビリティ・カンパニー 組み換え型骨形態形成蛋白ヘテロダイマー、組成物および使用法
US6479055B1 (en) * 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
US6471956B1 (en) 1994-08-17 2002-10-29 The Rockefeller University Ob polypeptides, modified forms and compositions thereto
US6124448A (en) * 1994-08-17 2000-09-26 The Rockfeller University Nucleic acid primers and probes for the mammalian OB gene
US6350730B1 (en) 1994-08-17 2002-02-26 The Rockefeller University OB polypeptides and modified forms as modulators of body weight
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6048837A (en) * 1994-08-17 2000-04-11 The Rockefeller University OB polypeptides as modulators of body weight
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6429290B1 (en) 1994-08-17 2002-08-06 The Rockefeller University OB polypeptides, modified forms and derivatives
US6936439B2 (en) * 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
US20030040467A1 (en) * 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
AU1520097A (en) * 1995-12-27 1997-07-28 Genentech Inc. Ob protein derivatives having prolonged half-life
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
AU769250B2 (en) * 1995-12-27 2004-01-22 Genentech Inc. OB protein derivatives having prolonged half-life
US20050019325A1 (en) 1996-01-08 2005-01-27 Carter Paul J. WSX receptor agonist antibodies
US7074397B1 (en) * 1996-01-08 2006-07-11 Genentech, Inc. Method for enhancing proliferation or differentiation of a cell using ob protein
US6541604B1 (en) * 1996-01-08 2003-04-01 Genentech, Inc. Leptin receptor having a WSX motif
EP0877627A1 (fr) * 1996-01-25 1998-11-18 Eli Lilly And Company Composes d'analogues de proteines de l'obesite et preparations a base de ceux-ci
US7067472B1 (en) * 1996-06-04 2006-06-27 The Scripps Research Institute Diagnostic and therapeutic methods related to regulating energy mobilization with OB protein and OB antibodies
US6001816A (en) * 1996-06-20 1999-12-14 Merck & Co., Inc. Gene therapy for leptin deficiency
US20060205660A1 (en) * 1996-06-20 2006-09-14 Sauvage Frederic D OB protein-immunoglobulin chimeras
US20030036629A1 (en) * 1997-12-12 2003-02-20 Barry Foster Novel tgf-beta protein purification methods
US6656906B1 (en) 1998-05-20 2003-12-02 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
US6420339B1 (en) * 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
US7169889B1 (en) * 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
CZ299516B6 (cs) 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
PE20010288A1 (es) 1999-07-02 2001-03-07 Hoffmann La Roche Derivados de eritropoyetina
CA2447632C (fr) * 2000-06-16 2011-08-02 Asterion Limited Agoniste d'une proteine hybride comprenant une partie se liant a une hotmone de croissance et un domaine externe d'un recepteur d'hormone de croissance
KR20030005204A (ko) * 2000-12-25 2003-01-17 가부시키가이샤 시세이도 교감신경 활성화 향료 조성물
US6867183B2 (en) * 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7060675B2 (en) * 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
EP1234583A1 (fr) * 2001-02-23 2002-08-28 F. Hoffmann-La Roche Ag Conjugués du PEG et du HGF-NK4
US6828297B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7713932B2 (en) * 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US6835802B2 (en) 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US6828305B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6713452B2 (en) 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6913903B2 (en) * 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7166571B2 (en) * 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7030082B2 (en) * 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US7312192B2 (en) * 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7196059B2 (en) * 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
WO2003034996A2 (fr) 2001-10-22 2003-05-01 Amgen, Inc. Utilisation de leptine pour traiter la lipoatrophie humaine et procede pour determiner une predisposition a ce traitement
WO2003092614A2 (fr) * 2002-05-02 2003-11-13 Hickle Randall S Systeme et procedes d'elimination de lipides du corps
RU2363478C2 (ru) 2003-09-12 2009-08-10 Вайет Инъецируемые стержни из фосфата кальция для доставки остеогенных белков
UA91512C2 (ru) 2004-07-19 2010-08-10 Биокон Лимитед Коньюгати олигомеров инсулина, их композиция (варианты) и применение
US8642543B2 (en) * 2005-09-07 2014-02-04 Neurotez, Inc. Methods for treating progressive cognitive disorders related to neurofibrillary tangles
US8227408B2 (en) * 2005-09-07 2012-07-24 Neurotez, Inc. Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology
US9241908B2 (en) * 2007-10-16 2016-01-26 Biocon Limited Orally administrable solid pharmaceutical composition and a process thereof
CA2742600A1 (fr) * 2008-11-04 2010-05-14 Nikolaos Tezapsidis Compositions a base de leptine et methodes de traitement de troubles evolutifs de la fonction cognitive provoques par une accumulation d'enchevetrements neurofibrillaires et de beta-amyloide
JP2012523434A (ja) 2009-04-10 2012-10-04 アミリン・ファーマシューティカルズ，インコーポレイテッド エストロゲン欠乏哺乳類のためのアミリンアゴニスト化合物
EA032917B1 (ru) 2010-09-28 2019-08-30 Амилин Фармасьютикалс, Ллк Сконструированные полипептиды, характеризующиеся увеличенной продолжительностью действия
CA2825683A1 (fr) 2011-01-26 2012-08-02 Novo Nordisk A/S Derives de leptine
US20230002447A1 (en) * 2019-12-03 2023-01-05 Rodan & Fields, Llc Peptides and compositions for inhibiting hair growth

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4199337A (en) * 1978-10-06 1980-04-22 International Telephone And Telegraph Corporation Method of fabricating high strength optical preforms
US4666836A (en) * 1981-01-02 1987-05-19 The Research Foundation Of State University Of New York Novel cloning vehicles for polypeptide expression in microbial hosts
US4609546A (en) * 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4757013A (en) * 1983-07-25 1988-07-12 The Research Foundation Of State University Of New York Cloning vehicles for polypeptide expression in microbial hosts
US4643969A (en) * 1983-07-25 1987-02-17 The Research Foundation Of State University Of New York Novel cloning vehicles for polypeptide expression in microbial hosts
EP0154316B1 (fr) * 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Lymphokine chimiquement modifiée et son procédé de préparation
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5643575A (en) * 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
AU3329895A (en) * 1994-08-17 1996-03-07 Rockefeller University, The Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US5861485A (en) * 1994-08-23 1999-01-19 Millennium Pharmaceuticals, Inc. Polypeptides involved in body weight disorders, including obesity
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5827734A (en) * 1995-01-20 1998-10-27 University Of Washington Materials and methods for determining ob protein in a biological sample
US5563243A (en) * 1995-01-31 1996-10-08 Eli Lilly And Company Anti-obesity proteins
US5574133A (en) * 1995-01-31 1996-11-12 Eli Lilly And Company Anti-obesity proteins
US5563244A (en) * 1995-01-31 1996-10-08 Eli Lilly And Company Anti-obesity proteins
US5567678A (en) * 1995-01-31 1996-10-22 Eli Lilly And Company Anti-obesity proteins
US5559208A (en) * 1995-01-31 1996-09-24 Eli Lilly And Company Anti-obesity proteins
US5580954A (en) * 1995-01-31 1996-12-03 Eli Lilly And Company Anti-obesity proteins
US5569744A (en) * 1995-01-31 1996-10-29 Eli Lilly And Company Anti-obesity proteins
US5569743A (en) * 1995-01-31 1996-10-29 Eli Lilly And Company Anti-obesity proteins
US5554727A (en) * 1995-01-31 1996-09-10 Eli Lilly And Company Anti-obesity proteins
US5563245A (en) * 1995-01-31 1996-10-08 Eli Lilly And Company Anti-obesity proteins
US5567803A (en) * 1995-01-31 1996-10-22 Eli Lilly And Company Anti-obesity proteins
US5594104A (en) * 1995-01-31 1997-01-14 Eli Lilly And Company Anti-obesity proteins
WO1996023515A1 (fr) * 1995-01-31 1996-08-08 Eli Lilly And Company Proteines anti-obesite
AU5539596A (en) * 1995-04-06 1996-10-23 Amylin Pharmaceuticals, Inc. Anti-obesity agents
EP0832220A1 (fr) * 1995-06-07 1998-04-01 Amgen Inc. Compositions renfermant la proteine ob et procedes associes
AU1406497A (en) * 1995-12-06 1997-06-27 Schering Corporation Mutational variants of mammalian ob gene proteins
AU1520097A (en) * 1995-12-27 1997-07-28 Genentech Inc. Ob protein derivatives having prolonged half-life

Also Published As

Publication number Publication date
HUP9601120A3 (en) 1999-07-28
PL186568B1 (pl) 2004-01-30
JPH093098A (ja) 1997-01-07
CN1157290A (zh) 1997-08-20
HUP9601120A2 (en) 1996-11-28
TR199600357A2 (tr) 1996-11-21
SK56996A3 (en) 1997-04-09
MY132189A (en) 2007-09-28
NZ286466A (en) 1998-03-25
DE741187T1 (de) 1997-04-30
EP0741187A2 (fr) 1996-11-06
TW464655B (en) 2001-11-21
JP3244627B2 (ja) 2002-01-07
BG100558A (bg) 1997-03-31
HRP960213A2 (en) 1997-10-31
HU9601120D0 (en) 1996-06-28
KR960041194A (ko) 1996-12-19
CA2175298A1 (fr) 1996-11-06
HU220093B (hu) 2001-10-28
UY24219A1 (es) 2001-03-16
BR9602166A (pt) 1998-01-13
CZ129796A3 (en) 1997-01-15
BG62975B1 (bg) 2000-12-29
SV1996000030A (es) 1999-01-14
PL314051A1 (en) 1996-11-12
TNSN96066A1 (fr) 2005-03-15
AU5197896A (en) 1996-11-14
RO117177B1 (ro) 2001-11-30
SG49337A1 (en) 1998-05-18
EP0741187A3 (fr) 1996-12-11
GR960300075T1 (en) 1996-12-31
RU96109211A (ru) 1998-10-27
AR003087A1 (es) 1998-07-08
US6025325A (en) 2000-02-15
IS4343A (is) 1996-12-09
YU26596A (sh) 1999-03-04
NO961796D0 (no) 1996-05-03
ES2093593T1 (es) 1997-01-01
NO961796L (no) 1996-11-06
IL118059A0 (en) 1996-08-04
MX9601655A (es) 1997-07-31
KR100219970B1 (ko) 1999-10-01
PE50897A1 (es) 1997-12-19
AU688210B2 (en) 1998-03-05
OA10362A (fr) 2001-11-15

Similar Documents

Publication Publication Date Title
MA23856A1 (fr) Recombinant obese (ob) proteines
DE69735926D1 (de) Interleukin-18 Rezeptorproteine
NO2010013I1 (no) Rekombinant FSH-CTP
NO985680L (no) Peptidderivater
NO976058L (no) Rekombinant mistellectin
BR9610239A (pt) Proteínas de fusão-alérgeno-xcd32
NO983849D0 (no) Peptidderivater
ZA963530B (en) Recombinant obese (ob) proteins
DE69427363D1 (de) Plättchenaggregationsinhibierende peptide
ID19257A (id) Protein-protein anti-obesitas
BR9606756A (pt) Peptídeo
NO981052D0 (no) Peptidderivater
NO20005547D0 (no) Myelinbasiske proteinpeptider og anvendelser derav
NO981051D0 (no) Peptidderivater
ID16711A (id) Protein-protein obese (ob) rekombinan
DE69615850D1 (de) G-protein-gekoppelter rezeptor hnfd578
NO20006091D0 (no) Humant protein C-polypeptid
SE9502007D0 (sv) Novel polypeptides
SE9504467D0 (sv) Peptide
BR1100812A (pt) Peptìdeo
ITMI951328A0 (it) Peptidi multimerici
NO973515D0 (no) Anti-fedme proteiner
SE9601085D0 (sv) Novel polypeptides
SE9602361D0 (sv) Plant proteins/peptides
ITMI972543A1 (it) Proteina p27bbp